Cargando…
Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience
BACKGROUND AND AIMS: Hepatitis C virus (HCV) infection is associated with extrahepatic manifestations such as cryoglobulinemia and accounts for up to 90% of all cases of mixed cryoglobulinemia (MC). The present study aimed to evaluate the effect of sofosbuvir–daclatasvir therapy on symptomatic HCV-r...
Autores principales: | Hassan, Amro M, Osman, Heba A, Mahmoud, Hasan S, Hassan, Mohammed H, Hashim, Abdel-Kader A, Ameen, Hesham H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027820/ https://www.ncbi.nlm.nih.gov/pubmed/29983581 http://dx.doi.org/10.2147/IDR.S167093 |
Ejemplares similares
-
Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]
Publicado: (2019) -
Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016) -
Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir
por: Ashraf, Taha, et al.
Publicado: (2017) -
The ameliorating role of sofosbuvir and daclatasvir on thioacetamide-induced kidney injury in adult albino rats
por: Moustafa, Ahmed H., et al.
Publicado: (2023) -
Hepatic effect of sofosbuvir and daclatasvir in thioacetamide-induced liver injury in rats
por: Ibrahim, Mohamed A., et al.
Publicado: (2018)